Despite the importance of Aβ aggregation in Alzheimer's disease etiology, our understanding of the sequence determinants of aggregation is sparse and largely derived from in vitro studies. For example, in vitro proline and alanine scanning mutagenesis of Aβ 40 proposed core regions important for aggregation. However, we lack even this limited mutagenesis data for the more disease-relevant Aβ 42 . Thus, to better understand the molecular determinants of Aβ 42 aggregation in a cell-based system, we combined a yeast DHFR aggregation assay with deep mutational scanning.
Introduction
Protein aggregation affects all known organisms from bacteria to humans and is implicated in a number of human diseases. Decades of genetic, biochemical and epidemiological work suggests that aggregation of the amyloid β (Aβ) peptide is related to the incurable neurodegeneration associated with Alzheimer's disease (Hardy and Selkoe 2002; Lesné et al. 2008; Bertram and Tanzi 2008; Shankar et al. 2009; Masters and Selkoe 2012; Hardy 2017) . Aβ peptide is generated by post-translational cleavage of the transmembrane amyloid β precursor protein at variable positions to produce peptides that range from 38 to 43 amino acids in length. The most aggregation-prone form of Aβ is 42 amino acids long (Aβ 42 ), though Aβ 40 is present at higher concentrations in human cerebrospinal fluid (Jarrett et al. 1993; Iwatsubo et al. 1994; Dahlgren et al. 2002) . The aggregation of Aβ begins with a shift in equilibrium from soluble monomers to oligomers, and these oligomers may nucleate amyloidogenesis (Matsumura et al. 2011; Barz et al. 2018) . In Alzheimer's disease, Aβ fibrils accumulate in the extracellular space forming the major component of amyloid plaques, a defining feature of the disease.
Despite the importance of Aβ aggregation in Alzheimer's disease etiology, our understanding of the sequence determinants of aggregation is sparse and largely derived from in vitro studies. In the past decade, several assays based on the budding yeast S. cerevisiae have been used to study protein aggregation (Bagriantsev and Liebman 2006; Haar et al. 2007; Caine et al. 2007; Morell et al. 2011; D'Angelo et al. 2013) . Notably, a growth-based assay that separates toxicity from aggregation offers a way to investigate how changes in Aβ sequence impact aggregation propensity (Morell et al. 2011) (Figure 1A) . In this assay, Aβ is cytoplasmically localized to eliminate its aggregation-associated toxicity (Treusch et al. 2011; D'Angelo et al. 2013) . To link Aβ aggregation to yeast growth, Aβ is fused to an essential protein, dihydrofolate reductase (DHFR) via a short peptide linker. The result is that DHFR activity depends on the solubility of Aβ. Thus, upon treatment with the competitive DHFR inhibitor methotrexate, yeast expressing soluble Aβ variants grow rapidly, whereas yeast expressing aggregating Aβ variants grow slowly.
Mutagenesis can elucidate the role of individual residues in protein aggregation. For example, in vitro proline (Williams et al. 2004 ) and alanine (Williams, Shivaprasad, and Wetzel 2006a) scanning mutagenesis of Aβ 40 revealed core regions important for aggregation. However, we lack even this limited mutagenesis data for the more disease-relevant Aβ 42 and, so far, the majority of mutagenesis studies have been performed in vitro.
Thus, to fully understand the molecular determinants of Aβ 42 aggregation in a cell-based system, we combined the yeast DHFR aggregation assay with deep mutational scanning (Araya and Fowler 2011; to measure the effect of 791 of the possible 798 single amino acid substitution on the aggregation propensity of Aβ 42 . We used high-throughput DNA sequencing to track the frequency of each Aβ 42 variant during the selection, enabling us to assign a solubility score to every variant. We present the first large-scale, cell-based mutational analysis of Aβ, illuminating the physicochemical properties of amino acids that abrogate, promote or do not effect Aβ aggregation. Of 791 single amino acid Aβ variants we evaluated, ~75% maintained or increased aggregation. In addition, we identified 11 positions at which substitutions, particularly to hydrophilic and charged amino acids, disrupted Aβ aggregation. These critical positions were similar but not identical to critical positions identified in previous Aβ mutagenesis studies. Finally, we analyzed our large-scale mutagenesis data in the context of different Aβ aggregate structural models, finding that some structures were plausible whereas others were not.
METHODS

Library construction
The library was cloned using in vivo assembly (García-Nafría et al. 2016) . First, a forward primer containing a 5' homology region, an NNK codon, and a 3' extension region was designed for each codon in Aβ 42 . The homology and extension regions were at least 15 nucleotides in length and had melting temperatures greater than 55C.
Reverse primers were the reverse complement of the 5' homology region. 
Plasmids, yeast strains and growth conditions
To create a galactose-regulated Aβ-DHFR expression system, we cloned the human Aβ 42 coding sequence into the SpeI and HindIII sites of p416 (URA3, GAL1 promoter, & Funk, 1994) . Aβ-GFP variants were cloned using the same scheme. All Aβ variants were cloned into p416 and transformed in W303 strain (MATa/MATα {leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15} [phi+]). Cells were grown at 30C in synthetic complete (SC) media lacking uracil and supplemented with 2% glucose.
Methotrexate selection assay
Transformed yeast were inoculated into 5 mL (low-throughput) or 300 mL (deep mutational scan) of C-Ura, 2% glucose media, grown in a rotating/shaking, 30C
incubator overnight and then transferred to 5 mL or 300 mL 2% raffinose media to remove the glucose repression acting on the gal1 promoter. After two hours in 2% raffinose, yeast were back-diluted to an OD of 0.01 into 5 mL or 300 mL 2% galactose to induce Aβ 42 -DHFR expression in the presence or absence of 80 μ Μ methotrexate (TCI America, M-1664), 1 mM sulfanilamide (Sigma, S-9251). For 300 mL experiments, wherein yeast with aggregating and nonaggregating variants were grown in co-culture, the two strains were inoculated at equally densities. In 5 mL experiments, yeast growth was measured using a spectrophotometer that detects 660 nm wavelengths over a 48h
course. In competition experiments, 10 OD units of yeast were collected from 300 mL cultures every 12h, spun down, concentrated and stored in -80C. At the end of the experiment, frozen yeast were thawed and then their plasmids were extracted using a DNA Clean and Concentrator kit (Zymo Research, D4013). Extracted plasmids were prepped and sequenced using Sanger sequencing. The following equation was used to calculate doubling times from two time points: (Log 10 (OD T2 /OD T1 )/ Log 10 (2))/ Δ Τ , where OD represents the optical density at 600nm at a time point (T).
Library preparation for high-throughput sequencing
Plasmids were extracted from yeast with Yeast Plasmid Miniprep 1 kit (Zymo Research, D-2001). Library fragments were amplified in 17 PCR cycles using primers specific to DNA sequences that flank Aβ-DHFR in p416, and sequenced by an Illumina NextSeq sequencer using paired-end reads ( Table S1) .
Variant effect analysis
Enrich2 was used to calculate solubility scores for each Aβ variant from sequencing fastq files (Rubin et al. 2017) . The Enrich2 pipeline calculates a variant's score in three steps. First, a variant's normalized frequency ratios are tabulated for each timepoint by dividing the frequency of a variant's sequencing reads by all mapped reads and normalizing by the wild-type frequency ratio. Sequencing reads were stringently filtered for quality by requiring each base have a Phred score greater than 20 and no uncalled bases. Second, a weighted linear least squares regression line is fit to the normalized frequency ratios across time. Third, the slope of the regression line is calculated and averaged across the three replicates. This averaged slope reflects a variant's aggregation propensity. Solubility scores below 0 denote variants that are more aggregation-prone than wild-type, whereas scores above 0 indicate that a variant has increased solubility compared to wild-type.
Classifying Aβ variants using synonymous mutations
Variant classifications (i.e., WT-like, more aggregation-prone, more soluble) were assigned using the distribution of 39 synonymous mutations from the deep mutational scan. We define WT-like as any variant with a score within ±2 standard deviations of the synonymous variant mean [-0.26,0.39] . A variant is more-aggregation prone than wildtype if its score is greater than 0.39 or more soluble if its score is lower than -0.26.
Data and code availability
Raw sequencing data will be made available upon publication in the NCBI GEO database. Code is available at https://github.com/FowlerLab/amyloidBeta2019.
Results
First, we verified that the DHFR-based yeast aggregation assay could differentiate between aggregating wild type Aβ (Aβ WT ) and a nonaggregating (Aβ F19D ) variant (Morell et al. 2011) . As expected, in a mixed culture treated with methotrexate, Aβ F19D
outcompeted Aβ WT (Figure 1B) . We used fluorescence microscopy of Aβ-GFP fusions to confirm that 49% of yeast expressing Aβ WT -GFP had cytoplasmic punctae compared to 6% of cells expressing Aβ F19D -GFP (Figure 1C-D) . Thus, we concluded the assay could be used in a deep mutational scan to measure the aggregation propensity of variants of Aβ.
Using this assay, we conducted a deep mutational scan of Aβ that yielded solubility scores for 791 single amino acid variants, representing 99.1% of the possible single variants. Solubility scores were calculated by taking the weighted least squares slope of each variant's frequency ratios across six time points. (see Methods). The slopes from each replicate were well correlated (Pearson's R 0.78 to 0.92; Figure 2A , Figure S1A ).
Replicate slopes were averaged and normalized to produce final solubility scores such that wild-type had a solubility score of zero (Table S2 ). Positive solubility scores indicated less aggregation and negative scores indicated increased aggregation.
Solubility scores ranged from -2.38 (most aggregating) to 1.45 (most soluble). The mean (median) solubility score for all variants was 0.09 (0.08), which was similar to the solubility scores of the 39 synonymous variants in our library (mean: 0.06; median: 0.08). Because we did not expect synonymous variants to affect aggregation propensity, we used their distribution of scores to identify WT-like variants (Figure 2B) .
In total, we found that 344 (43.4%) of Aβ variant scores were within two standard deviations of the synonymous score mean and thus had WT-like effects (WT-like range:
[-0.26,0.39]). Additionally, we found 246 (31.1%) variants to be more aggregation-prone than Aβ WT and 201 (25.4%) variants to be more soluble. Therefore, ~75% of Aβ variants maintained or increased the peptide's propensity to aggregate in yeast cells.
To verify that our deep mutational scan accurately measured variant effects on aggregation, we tested six Aβ variants, G38F, K16V, A42V, F19Y, L17S and L34R, that spanned the solubility score range in a low-throughput validation assay. The growth rate of methotrexate-treated yeast expressing each Aβ variant was measured and compared to the aggregation propensity scores (Figure 2C, S1B) . We found that the lowthroughput assay results strongly correlated with the solubility scores derived from deep mutational scanning (R 2 = 0.98). Thus, our assay reliably measured Aβ variant aggregation propensity.
To explore the effects of each amino acid substitution on Aβ aggregation, we created an Aβ sequence-aggregation map (Figure 2D) . Substitutions to aspartic acid and proline were most associated with Aβ solubility, as evinced by their median scores of 0.64 and 0.56, respectively (Figure S2A) . Conversely, the most aggregation-associated substitutions were hydrophobic tryptophan and phenylalanine, with scores of -0.60 and -0.51, respectively. Moreover, hierarchical clustering of all 791 solubility scores by amino acid revealed that hydrophobic substitutions, except alanine, clustered together and were associated with greater aggregation than other classes of substitutions.
Next, we characterized each position in Aβ based on its mutational profile. Hierarchical clustering of variant solubility scores by position identified six distinct clusters (Figures   2E-F; S2B-C) . In cluster 1, comprising positions 17-20, 31-32, 34-36, 39 and 41, substitutions tended to decrease Aβ aggregation compared to substitutions in other clusters (cluster 1 mean solubility scores = 0.64, all other clusters = -0.28; Figure S2D ).
In cluster 1, even substitutions to hydrophobic amino acids slightly decreased aggregation (mean solubility score = 0.17). The effects of substitutions in cluster 2 were similar to but less extreme than in cluster 1. Both clusters 1 and 2 are largely Next, we compared our solubility scores to previous alanine and proline scans which reported Aβ 40 fibril thermodynamic stability in vitro (ΔΔG).
Δ Δ
G values were determined by measuring variant Aβ monomer concentration remaining in solution after fibril formation reached equilibrium (Williams et al. 2004; Williams, Shivaprasad, and Wetzel 2006a) . We found that the effects of proline substitution in our assay were correlated with proline Δ Δ G values (R 2 = 0.40), while the effects of alanine substitutions in our assay were less correlated with alanine Δ Δ G values (R 2 = 0.17; Figure 3A) . In our alanine and proline comparisons, we found the greatest correlation at positions 17-20
and 31-32, where substitutions decreased aggregation in all studies (Figure S3) . At positions 1-9 alanine or proline substitutions had smaller effects on aggregation. The most notable disagreement between studies was for alanine substitutions at positions 37 and 38. In our assay, alanine substitutions caused a profound increase in aggregation, whereas the in vitro alanine scan showed the opposite effect.
We also compared the buried β -stand positions we proposed based on our deep mutational scanning data to β -stands proposed based on the alanine and proline scans, finding some concordance (Figure 3B) . The single amino acid scans identify three regions that disrupt fibril elongation thermodynamics when mutated. The regions include positions 15-21, 24-28, and 31-36 for the proline scan and positions 18-21, 25-26, and 32-33 for the combined alanine and proline scans (Williams et al. 2004; Williams, Shivaprasad, and Wetzel 2006b) . Given the generally highly disruptive nature of proline substitutions (Gray et al. 2017) , it is not surprising that the proline scan would nominate many positions. Our deep mutational scan, on the other hand, does not reveal a central β -strand or strong decrease in aggregation with alanine or proline substitution from positions 24-28. We speculate that this difference is due either to the distinct experimental approaches used or to the different Aβ species (Aβ 40 vs. Aβ 42 ).
Discussion
We used deep mutational scanning to characterize 791 Aβ variants in a yeast-based aggregation assay. Proline and aspartic acid substitutions were most disruptive of Aβ aggregation, while tryptophan and phenylalanine increased aggregation most.
Additionally, we used unsupervised clustering to determine the regions of Aβ most important for aggregation. We conclude that these regions are most likely to form buried β -stands, which are necessary for aggregation and sensitive to amino acid substitutions (Jahn et al. 2010; Abrusán and Marsh 2016) . Gregory et al. 1998; Antzutkin et al. 2002; Tycko 2011) . Many of these structural models are problematic because they are generated from constraints derived from in vitro experimental data, which may not be representative of in vivo conditions.
Given that we collected large-scale mutagenesis data in a cell-based system, we examined how our results compared to structural models of Aβ fibrils. Some models such as 1IYT (Crescenzi et al. 2002) and 2NAO (Wälti et al. 2016) , showed very little to no overlap with either our proposed buried β -strands or those proposed by Williams et al. (2004 Williams et al. ( , 2006 (Figure 3C) . Other models contained three β -strand regions reminiscent of those suggested by Williams et al. (2004 Williams et al. ( , 2006 : 2MXU (Xiao et al. 2015) , 5KK3 (Colvin et al. 2016) , and 5OQV (Gremer et al. 2017 ). Yet other models propose β -strand patterns more similar to ours. These include 2BEG (Lührs et al. 2005) ,
2LNQ (Gremer et al. 2017 ), 2LMP and 2LMN (Lu et al. 2013 ). Since our β -strands were derived from data gathered in a cell-based assay, we hypothesized that they would be most consistent with structural models based on in vivo-derived fibrils. Indeed, the 2LMP and 2LMN models were based on fibrils seeded from plaques isolated from the brains of individuals afflicted by Alzheimer's disease. Moreover, every model besides 2LMP and 2LMN was constructed using NMR or cryo-EM data from laboratory grown fibrils. That these models are less concordant with our cell-based mutational data suggests that there are important structural differences between in vitro and in vivo derived fibrils.
Deep mutational scanning data could contribute to the investigation of Aβ fibril structure beyond the analysis of existing models we present. For example, others have used sitesaturation mutagenesis and deep mutational scanning data to evaluate proposed structural models (Bajaj et al. 2008; Khare et al. 2019) . Additionally, deep mutational scanning data have now been used to generate distance constraints for the prediction of tertiary protein structure (Schmiedel and Lehner 2018; Rollins et al. 2018) .
In summary, we used deep mutational scanning to elucidate the effects of amino acid substitutions on Aβ aggregation in a cell-based model. We used these large-scale mutagenesis data to propose positions critical for Aβ aggregation. Our results conflict with some previous in vitro reports of the effects of substitutions on Aβ aggregation and with some models of Aβ fibril structure. This outcome highlights the difficulties of studying protein aggregation and emphasizes the potential utility of in vivo or cell-based models. We suggest that deep mutational scanning of other aggregation-prone proteins such as α -synuclein or transthyretin could help reveal the relationship between sequence, structure and aggregation. Figure S1A ). The distribution of solubility scores (x-axis) of synonymous variants was used to determine cutoffs that define variants that are wildtype-like or more/less aggregation-prone than wild-type. The density plot shows distributions of nonsynonymous (light gray) and synonymous (dark gray) variants and the white lines show the lower (-0.26) and upper (0.39) bounds for wild-type-like mutations (B). The scatterplot shows the correlation between our solubility scores (yaxis) and a low-throughput yeast growth assay that measured yeast growth rate as a proxy for Aβ solubility (C; Figure S1B ). The heatmap shows the effect of 791 Aβ variants on solubility with Aβ positions on the x-axis and mutant amino acids on the yaxis. A variant's color denotes its solubility: red is most soluble, white is wild-type-like and, dark blue is most aggregated, whereas yellow variants are missing from our variant library and dots denote the wild-type amino acid at a given position. The annotation tracks on the x-and y-axes display the hydrophobicity of each wild-type and mutant amino acid, respectively. The heatmap's y-axis has been re-ordered using hierarchical clustering on the solubility score vectors (D). For each position, the mean solubility score at each position is depicted using the same color scheme as the main heatmap.
Figure Legends
Additionally, the mean solubility scores for all hydrophobic and polar substitutions are shown (E; Figure S2A ). Heirarchical clustering on the x-axis yielded 6 distinct clusters:
1 (red), 2 (orange), 3 (yellow), 4 (green), 5 (light blue), and 6 (dark blue; F; Figure S2B -C). 
